Pharmaceutical Business Review
Anonymous User | Login

Abraxis BioScience Q4 net loss widens to $181.9m

Published: 06-Mar-2009

Net revenue increased by 1.5%

Abraxis BioScience, a fully integrated biotechnology company, has reported a net loss of $181.9m, or $4.54 per share, for the fourth quarter of 2008, compared with a net loss of $5.2m, or $0.13 per share, for the fourth quarter of 2007.

Net revenue increased 1.5% to $92.2m for the fourth quarter of 2008, compared with $90.8m for the prior-year period.

For the full year 2008, net revenue increased 3.5% to $345.3m, compared with $333.7m for the prior year. The company reported a net loss of $276.8m, or $6.91 per share, for 2008, compared with a net loss of $41.6m, or $1.04 per share, in 2007.

Patrick Soon-Shiong, chairman and CEO of Abraxis BioScience, said: In 2008, we made considerable achievements building our Abraxane commercial franchise on a global basis. We established a new infrastructure in Europe and launched Abraxane in the UK, Australia, India and the United Arab Emirates.

With the early 2009 launch in Germany and approval to market Abraxane in China, Korea, together with the expected launches in the balance of the EU countries, we have substantial additional market opportunities for 2009 and beyond. Coupled with several strategic acquisitions and a reinforced infrastructure, we believe we are well poised for continued success.

Mail sent successfully

Tell your friend about this article


Please enter a valid email address

Please enter your name

Please enter the mail body


Your Name: *
Your Email: *
Friend's Email: *
Email Body: *
 

Suppliers To This Sector

Browse A-Z

# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

ADAPT Localization

The Translation and Localization Specialists ...

Anoto

Providing Unique Technology for Digital Pen and Paper ...

Aptuit

Drug Discovery and Development ...

Bachem

Process Development and Manufacturing of Peptides and Complex Organic Molecules as APIs ...

BaseCon

IT Pharma Solutions ...

Bioceros

Pre-Clinical Development of Monoclonal Antibodies and Generation of GMP-Ready Proteins ...

White Papers

Browse A-Z

# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

GRACO's New FDA Pumps

The Graco 3150 3A sanitary pump is designed to meet the stringent sanitation requirements ...

GRACO's New Hydra-Clean

The Graco 3150 3A sanitary pump is designed to meet the stringent sanitation requirements ...

GRACO's New 1590 & 3150 Pumps

The Graco 3150 3A sanitary pump is designed to meet the stringent sanitation requirements ...

Water Treatment

From the control room to the downstream processing area and with an eye on utilities servi ...

Customer Testimonial – Astra Zeneca

From the control room to the downstream processing area and with an eye on utilities servi ...

Hygienic Processing

From the control room to the downstream processing area and with an eye on utilities servi ...

Related Companies

No items to display

Suppliers Product News

Organisations Throwing Mobile Technology at Problems With Little Consideration of Actual User and Business Needs, Quocirca

Survey reveals detrimental impact on organisational effectiveness and IT expenditure in healthcare and finance across the UK, France, Germany and the US.

Digital Pen and Paper Technology Helps Accelerate Clinical Trials

Digital pen and paper technology captures handwritten clinical data electronically, quickly and securely to save time and cost in drug discovery process.

Aptuit Outlines 2010 Business Priorities at 28th Annual J.P. Morgan Healthcare Conference

Aptuit, Inc., a contract development and manufacturing company, today will provide an update on 2010 business priorities and discuss its integrated service offerings at the 28th Annual J.P. Morgan Healthcare Conference in San Francisco.

Aptuit Publishes Study which Demonstrates the Value of Early Insights into the Characterisation of Drug Compounds

New research on the solid-state characterisation of finasteride clearly outlines a systematic approach to characterising and monitoring active pharmaceutical ingredients

Aptuit Launches Program to Accelerate Early Stage Drug Development

Aptuit INDiGO™ accelerates drug development from pre-clinical candidate selection to regulatory filing on a fixed timeline and price

mondoBIOTECH and Bachem Agree Long-Term Cooperation on the Development of Peptides to Fight Rare Diseases

mondoBIOTECH and Bachem on 24 September announced the conclusion of a longterm cooperation.

Free Newsletter Sign-up

Sign up, and we will send you a free Pharmaceutical report on “ Combination Products – Evolution of the Medical Equipment Industry” from GlobalData worth $750

Please enter a valid email address